Atara Biotherapeutics, Inc. (ATRA)

NMS – Real Time Price. Currency in USD

9.81

+1.03 (11.73%)

At close: May 12, 2026, 4:00 PM EDT

9.50

-0.31 (-3.16%)

After-hours: May 12, 2026, 7:59 PM EDT

12.05.2026

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) and certain officers. The class action, filed in the United States District Court for the Central District of California, and docketed under 26-cv-03083, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Atara securities between May 20, 2024 and January 9, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

12.05.2026

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2026 and business updates. Tabelecleucel (tab-cel® or Ebvallo™) for Post-Transplant Lymphoproliferative Disease (PTLD) As previously communicated, Pierre Fabre Pharmac.

12.05.2026

Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

LOS ANGELES, May 12, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 22, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) securities between May 20, 2024 and January 9, 2026, inclusive (the “Class Period”).

12.05.2026

ATARA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

New York, New York--(Newsfile Corp. - May 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026, inclusive (the "Class Period"), of the important May 22, 2026 lead plaintiff deadline. SO WHAT: If you purchased Atara securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

12.05.2026

Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors

LOS ANGELES, May 12, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Atara Biotherapeutics, Inc., (“Atara” or the "Company") (NASDAQ: ATRA) investors of a class action on behalf of investors that bought securities between May 20, 2024 and January 9, 2026, inclusive (the “Class Period”). Atara investors have until May 22, 2026 to file a lead plaintiff motion.

12.05.2026

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA

NEW YORK, May 12, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Atara Biotherapeutics, Inc. (NASDAQ: ATRA). Shareholders who purchased shares of ATRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

11.05.2026

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026, inclusive (the “Class Period”), of the important May 22, 2026 lead plaintiff deadline.

Videos

No Data

There is no data to display

Press releases

12.05.2026

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

12.05.2026

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

12.05.2026

Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

12.05.2026

ATARA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

Atara Biotherapeutics, Inc. (ATRA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Atara Biotherapeutics, Inc. (ATRA)

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

ATARA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

Videos

No Data

Press releases

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

ATARA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

ATARA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

Videos

No Data

Press releases

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

ATARA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

Search stocks

Atara Biotherapeutics, Inc. (ATRA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Atara Biotherapeutics, Inc. (ATRA)

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

ATARA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

Videos

No Data

Press releases

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

ATARA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

ATARA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

Videos

No Data

Press releases

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

ATARA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA